View sample - Report Buyer

1.1 List of Tables
Table 1: Type 1 Diabetes Therapeutics Market, Global, Revenues ($bn), 2001-2009 ............................ 7
Table 2: Type 1 Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2017 ............. 8
Table 3: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Efficacy, 2010...14
Table 4:
Type 1 Diabetes Therapeutics Market, Lantus, Adverse Events in 28-Week Clinical Trials of
Adults and Children With Type 1 Diabetes, 2010 .....................................................................14
Table 5: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Safety, 2010 .....15
Table 6: Humulin - Glycemic Parameters at the End of Treatment Period in Randomized Patients in
Three Months Cross-Over Studies for Type 1 Diabetes, 2010 .................................................16
Table 7: Humulin – Results of Three Month Cross-Over Studies Comparing Humulin with Humalog in
Type 1 Diabetes, 2010..............................................................................................................17
Table 8: Type 1 Diabetes Therapeutics Market, Humalog, Glycemic Parameters at the End of
Treatment Period in Randomized Patients in Three Months Cross-Over Studies, 2010 ..........18
Table 9: Humalog – Results of a Two Month Study Comparing the Use of Humalog and Humulin With
Sulfonyluria (SU) Therapy, 2010...............................................................................................19
Table 10: Type 1 Diabetes Therapeutics Market, Novolog, Glycemic Parameters at the End of 24 Week
Study, 2010...............................................................................................................................20
Table 11: Apidra – Efficacy Result of 26-Week Study Comparing Apidra with Insulin Lispro, 2010 .........22
Table 12: Apidra – Efficacy Result of 26-Week Study Comparing Apidra with Regular Insulin ................22
Table 13: Apidra – Adverse Reactions Observed in Pooled Studies in Type 1 Diabetic Adults, 2010......22
Table 14: Levemir – Efficacy Result in 16-Week Non Blinded Study, 2010..............................................23
Table 15: Major Marketed Products Comparison in the Type 1 Diabetes Therapeutics Market, 2010.....24
Table 16: Type 1 Diabetes Therapeutics – Most Promising Drugs Under Clinical Development, 2010....27
Table 17: Type 1 Diabetes Therapeutics – Filed and Approved Drugs, 2010...........................................32
Table 18: Type 1 Diabetes Therapeutics – Phase III Clinical Pipeline, 2010............................................33
Table 19: Type 1 Diabetes Therapeutics – Phase II Clinical Pipeline, 2010.............................................33
Table 20: Type 1 Diabetes Therapeutics – Phase I Clinical Pipeline, 2010..............................................35
Table 21: Type 1 Diabetes Therapeutics – Preclinical-Discovery Pipeline, 2010 .....................................35
Table 22: Genzyme – Metabolic Disorders Marketed Products, 2010 ......................................................40
Table 23: Novo Nordisk - Metabolic Disorders Pipeline Products, 2010...................................................41
Table 24: GlaxoSmithKline – Metabolic Disorders Marketed Products, 2010...........................................43
Table 25: GlaxoSmithKline - Metabolic Disorders Pipeline Products, 2010..............................................43
Table 26: Eli Lilly – Metabolic Disorders Marketed Products, 2010 ..........................................................45
Table 27: Eli Lilly – Metabolic Disorders Pipeline Products, 2010 ............................................................45
Table 28: Sanofi-Aventis – Metabolic Disorders Marketed Products, 2010 ..............................................47
Table 29: Sanofi-Aventis – Metabolic Disorders Pipeline Products, 2010 ................................................47
1.2 List of Figures
Figure 1: Type 1 Diabetes Therapeutics Market, Global, Revenues ($bn), 2001-2009 ............................ 7
Figure 2: Type 1 Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2017 ............. 8
Figure 3: Opportunity and Unmet Need in the Type 1 Diabetes Therapeutics Market, 2010 ...................10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Type 1 Diabetes
Therapeutics, 2010 ...................................................................................................................13
Figure 5: Technology Trends Analytic Framework of the Type 1 Diabetes Therapeutics Pipeline, 2010.26
Figure 6: Technology Trends Analytic Framework of the Type 1 Diabetes Therapeutics
Pipeline – Description, 2010 .....................................................................................................27
Figure 7: Type 1 Diabetes Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 ........31
Figure 8: Type 1 Diabetes Therapeutics Pipeline by Phase of Clinical Development, 2010 ....................32
Figure 9: Implications for Future Market Competition in the Type 1 Diabetes Market, 2010....................37
Figure 10: Type 1 Diabetes Therapeutics Market – Clinical Pipeline by Company, 2010 ..........................39
Figure 11: GlobalData Methodology, 2010 ................................................................................................49
Figure 12: GlobalData Market Forecasting Model, 2010............................................................................52
Type 1 Diabetes - Drug Pipeline Assessment and
Market Forecasts to 2017
GDHC106PRT /Published JUN 2010
Page 5
© GlobalData. This report is a licensed product and is not to be photocopied